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Impact on survival of modelling increased surgical resection
rates in patients with non-small-cell lung cancer and
cardiovascular comorbidities: a VICORI study
Catherine A. Welch1,2, Michael J. Sweeting1,2, Paul C. Lambert1,3, Mark J. Rutherford1, Ruth H. Jack4, Douglas West5, David Adlam6 and
Michael Peake2,7
BACKGROUND: The impact of cardiovascular disease (CVD) comorbidity on resection rates and survival for patients with early-
stage non-small-cell lung cancer (NSCLC) is unclear. We explored if CVD comorbidity explained surgical resection rate variation and
the impact on survival if resection rates increased.
METHODS: Cancer registry data consisted of English patients diagnosed with NSCLC from 2012 to 2016. Linked hospital records
identified CVD comorbidities. We investigated resection rate variation by geographical region using funnel plots; resection and
death rates using time-to-event analysis. We modelled an increased propensity for resection in regions with the lowest resection
rates and estimated survival change.
RESULTS: Among 57,373 patients with Stage 1−3A NSCLC, resection rates varied considerably between regions. Patients with CVD
comorbidity had lower resection rates and higher mortality rates. CVD comorbidity explained only 1.9% of the variation in resection
rates. For every 100 CVD comorbid patients, increasing resection in regions with the lowest rates from 24 to 44% would result in 16
more patients resected and alive after 1 year and two fewer deaths overall.
CONCLUSIONS: Variation in regional resection rate is not explained by CVD comorbidities. Increasing resection in patients with
CVD comorbidity to the levels of the highest resecting region would increase 1-year survival.
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BACKGROUND
The impact of cardiovascular comorbidity on outcomes in patients
with non-small-cell lung cancer (NSCLC) is critical to clinical
decision-making but is complex and relatively poorly understood
in a real-world context. Patients with NSCLC have a dispropor-
tionally high rate of cardiovascular comorbidities1 since over 85%
are current or ex-smokers2 and the median age at diagnosis of
NSCLC is around 72 years. Curative surgical resection has the
potential to lead to long-term cancer-free survival in patients with
NSCLC3 leading to recent recommendations aiming to increase
the proportion of the resectable patient population treated with
surgery. However, lung resection is a major surgical procedure
with significant peri-operative risks, which increase in patients
with serious comorbidities, the most important of which are
cardiovascular and lung disease.4 Clinical decision-making in
NSCLC patients with cardiovascular disease (CVD) aims to find a
balance between the risk of adverse operative outcomes and the
potential prognostic gains of successful surgery. It is not known if
current practice strikes the right operative balance and whether
increasing lung resection in NSCLC patients with CVD has
significant potential to improve survival rates.
Historically, survival rates from lung cancer have been poor in
the UK and surgical resection rates have been low in comparison
to many other western countries.5 Data from the National Lung
Cancer Audit and the English Cancer Registries showed wide
variation in the proportion of patients undergoing surgical
resection between hospital trusts and commissioning areas in
England.6,7 Resection rates have increased significantly in England
in recent years as has 1- and 5-year survival6,8,9 but variation still
exists. Existing literature suggests further improvements in longer
term survival if the highest current resection rates could be
applied to all NSCLC patients in England.6,7 Very little is known
about the extent these low and variable resection rates can be
explained by differences in the rates of significant comorbidities.
Two studies comparing regional populations in the North East of
England and Italy have demonstrated that lower resection rates in
England can be explained, at least in part, by higher rates of
comorbidities.10,11
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As part of the Virtual Cardio-Oncology Research Institute
(VICORI), we used data from the Public Health England National
Cancer Registration and Analysis Service (NCRAS) linked with
Hospital Episode Statistics (HES) to identify CVD comorbidity
recorded in hospital records before a diagnosis of NSCLC. We
aimed first to investigate to what extent CVD comorbidities
explain geographical variation in surgical resection rates; second,
how CVD comorbidity affects operative outcome and third, how
CVD comorbidity affects survival in both the operated and non-
operated groups using a multi-state model. This sophisticated
statistical framework allows us to accurately model the whole
patient care pathway and has not previously been applied in this
context. Using this model, we can control for case-mix factors
between geographical regions (e.g. demographics, deprivation
indices, and other comorbidities) and model the effect of
standardising regional resection rates to the equivalent of the
highest fifth of current practice.
METHODS
Lung cancer population
We extracted data from 187,432 patients with 189,310 lung cancer
tumours (ICD10 C33-C34) diagnosed between 2012 and 2016 from
NCRAS linked to HES. Following exclusions (see Supplementary
Table 1), 161,231 patients remained. To create an analysis
population defined as potentially eligible for resection, we
included only patients with lung cancer diagnosed at stages 1, 2
or 3A (n= 57,373).
Patients who underwent surgical resection with curative intent
were identified from HES OPCS-4 (Office of Population Censuses
and Surveys Classification of Surgical Operations and Procedures
4th revision) codes recorded between 30 days before and 365 days
after cancer diagnosis (full list of codes in Supplementary Table 2).
OPCS-4 resection codes recorded outside this period (n= 973
more than 30 days before diagnosis, n= 380 more than 365 days
after diagnosis; 5.2%) were not considered as resections in the
analysis. Due to imprecision of some cancer diagnosis recording,
any resections up to 30 days before the recorded diagnosis date
were recoded to occur at the cancer diagnosis date (n= 510;
2.1%). Length of stay in hospital post-resection and re-admission
within 30 days of resection were identified in relation to admission
and discharge dates for the hospital admission associated with
resection. The length of time from NSCLC diagnosis to death or
censoring was calculated using vital status information from
NCRAS, with mortality follow-up until 28 January 2018.
Prior cardiovascular procedures and diagnosis codes
CVD procedures prior to cancer diagnosis were identified from
HES records (available from 1 January 2000) based on OPCS-4
procedure “K” codes and further subdivided into coronary artery
bypass graft (CABG), percutaneous coronary interventions (PCI),
valve surgery, diagnostic procedures and other CVD procedures
(Supplementary Table 3).
We also searched for any circulatory system diagnosis codes
(ICD10 I00−I99), which were categorised into eight groups
(Supplementary Table 3). Diagnosis and procedure codes were
used to create a four-level CVD severity exposure before NSCLC
diagnosis. The levels in order of severity are: (1) any previous
CABG, PCI or valve surgery CVD procedure, (2) no CVD procedure
but with any CVD diagnosis code (I00−I99, excluding patients with
only hypertension recorded), (3) only hypertension recorded or
other CVD procedure (not CABG, PCI or valve replacement)
without a CVD diagnosis code recorded, or (4) no history of any
CVD procedure or diagnosis codes recorded. No CVD procedure or
diagnosis codes was the reference group for all analyses.
We defined non-mutually exclusive exposure variables if the
following procedures/diagnoses were recorded at any time before
NSCLC diagnosis: (1) any CABG, (2) any PCI, (3) any valve surgery,
(4) only diagnostic procedures, (5) only other CVD procedures, (6)
CABG and PCI (in acute myocardial infarction (AMI) patients only),
(7) CABG and PCI (in non-AMI patients only), (8) CABG (in AMI
patients) and (9) PCI (in AMI patients). We also investigated the
effect of type of CVD diagnosis by defining the following exposure
variables: (1) AMI, (2) ischaemic heart disease (not AMI), (3)
congestive heart failure, (4) peripheral artery disease, (5) cerebro-
vascular disease, (6) stroke, (7) valvular heart disease, (8) any other
CVD diagnosis and (9) hypertension only. Each exposure category
was compared against no CVD procedure or diagnosis codes.
Independent variables
Socio-economic status was measured using the full Index of
Multiple Deprivation (IMD) 2015 score (https://www.gov.uk/
government/statistics/english-indices-of-deprivation-2015), which
measures area-level deprivation. We identified geographical
regions each patient was resident in at the time of NSCLC
diagnosis using Clinical Commissioning Groups, which are
clinically led statutory NHS bodies responsible for the planning
and commissioning of healthcare services for their local area. We
calculated the proportion of Stage 1−3A lung cancer patients
resident in each region who underwent resection and obtained
resection rate quintiles. Each region, and hence each patient
within that region, was assigned one of these fifths. Regional
resection quintiles were re-calculated based on the subgroup of
patients with CVD comorbidity (prior procedure or diagnosis). We
extracted cancer stage, morphology and the Charlson Comorbid-
ity Index (CCI)12 derived using comorbidities recorded in HES 27 to
3 months prior to NSCLC diagnosis. We derived a modified CCI,
which excluded CVD diagnosis codes, to avoid counting them in
both the CVD exposure and the CCI (Supplementary Table 4).
Statistical analysis
Variation in resection rates by geographical region. Funnel plots
were used to investigate variations in regional resection rates
by plotting standardised resection ratios (SRRs), calculated by
dividing the observed number of resections in each region by the
predicted number of resections, obtained from a logistic regres-
sion model.13 SRRs that fell outside the 99.8% confidence bands
were flagged. Logistic models progressively adjusted for main
effects of age at diagnosis, sex, cancer stage, CVD comorbidity
(four-level severity exposure), year of diagnosis (categorical), IMD
and the modified CCI. Non-linear effects of age-at-diagnosis were
modelled using a restricted cubic spline function with three knots.
Effect of CVD comorbidity on resection and mortality rates. We
used time-to-event analyses (Cox proportional hazards regression
and flexible parametric models14) to separately investigate the
association between CVD comorbidity and three outcomes: (1)
time from NSCLC diagnosis to resection, (2) time from NSCLC
diagnosis to death prior to or without resection, and (3) time from
resection to post-resection death. Time-to-event analyses were
used to account for competing risks of the three outcomes
(Supplementary Fig. 1). Predictors of post-operative death (30-day
mortality following resection) were also investigated using a
logistic regression model. All models adjusted for the same
variables used to assess regional resection rate variation along
with regional resection fifths. We tested the proportional hazards
assumption for all Cox regression models using Schoenfeld
residuals and in flexible parametric regression models we allowed
effects to be time-dependent (further details in Supplementary
Appendix 1). Patients were followed up until death or censoring.
We investigated if the time elapsed since the last recorded CVD
procedure before NSCLC diagnosis was associated with the rate of
resection and the mortality rate before and after resection.
Additionally, we investigated whether there were differential
effects by type of CVD comorbidity on the rate of resection.
The fitted flexible parametric models were used within a multi-
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state framework (Supplementary Fig. 1) to understand how
increasing the propensity of resection would affect overall survival
probabilities and restricted mean life-years15 (Supplementary
Appendix 2). Using standardisation,16 the marginal effect on
overall survival was predicted for patients in regions with the
lowest rates of resection (i.e. in the lowest fifth) and compared to
marginal estimates if they had resection rates of regions with the
highest rates of resection (i.e. the highest fifth), given the patient
mix (including CVD comorbidities) of these patients remained
unchanged. We repeated this analysis restricted to patients with a
CVD procedure or diagnosis, recalculating the regional resection
quintiles for this population. Further details are given in
Supplementary Appendix 2.
Finally, we performed a sensitivity analysis to investigate if
excluding NSCLC patients with cancer stage 3A changes the
findings because these patients are heterogeneous, i.e. the
standard of care is not consistent across England. We refit
the Cox proportional hazards regression model to investigate the
association between CVD comorbidity and time from NSCLC
diagnosis to resection (with the same progressive adjustments)
only including NSCLC patients with cancer stages 1 or 2.
RESULTS
Study population
Amongst the 161,231 patients with NSCLC diagnosed between
2012 and 2016, 11,030 (6.8%) had a CVD procedure (CABG, PCI or
valve surgery) prior to diagnosis, 70,224 (43.6%) had no CVD
procedure but had a CVD diagnosis (excluding patients with only
hypertension), 23,201 (14.4%) had only hypertension or a non-
interventional procedure code and 56,776 (35.2%) had no CVD
procedure or diagnosis codes recorded. The most prevalent CVD
diagnosis code was hypertension (n= 77,200; 47.9%), followed by
ischaemic heart disease and peripheral artery disease (Supple-
mentary Table 3).
Amongst the 57,373 patients with cancer stages 1, 2 or 3A,
patients with CVD comorbidity were on average older compared to
those without CVD and were more likely to be male, have a more
recent NSCLC diagnosis, belong to a higher category of multiple
deprivation and have a clinical diagnosis of lung cancer (i.e. not
morphologically confirmed) (Supplementary Table 5) (all p < 0.001).
Resection rates
The resection rate was 15.2% across all patients and 39.0%
amongst patients with clinical stages 1, 2 or 3A. The majority of
patients presented with late stage disease (55.1% stage 3B or 4 at
diagnosis and 9.3% missing stage information) (Table 1). Within
each stage of cancer diagnosis, resection rates were significantly
lower for patients with CVD procedures or diagnoses compared to
patients with no CVD (p < 0.001 for each cancer stage). In the
group of patients with stage 1 disease and no recorded CVD or
procedures (n= 7565), the resection rate was 62.8% compared
with only 44.4% in those patients with stage 1 disease who had a
CVD procedure (n= 2194). Patients with a CVD procedure were,
however, more likely to have stage 1 lung cancer compared with
patients with no CVD; 2194/11,030 (21.7%) of patients with a CVD
procedure compared with 7565/56,776 (14.4%) of patients with
no CVD.
Geographical variation
Resection rates for cancer stages 1−3A varied considerably
between geographical regions (from 20.6 to 64.6%) with variation
between regions greater than that expected due to chance (10/
209 (4.8%) regions had observed resection rates outside of the
99.8% confidence bands). Adjusting for case-mix, including CVD
comorbidity, did not substantially reduce the variation (Fig. 1).
CVD comorbidity explained only a small proportion of the overall
variation in resection rates (univariate Tjur R2= 1.9%).17 In
comparison, age explained 10.2% of the variation, cancer stage
9.1%, sex 0.1%, and CCI < 0.1%.
Risk of resection
Patients with a CVD procedure or diagnosis were less likely to be
resected compared to patients with no CVD (unadjusted hazard
ratios for CVD procedure and diagnosis were 0.71 (95% CI 0.67,
0.74) and 0.66 (95% CI 0.64, 0.68), respectively). After adjusting for
potential case-mix (including cancer stage, age and sex), the
hazard ratio for CVD procedure attenuated to 0.82 (95% CI 0.78,
0.87) and for CVD diagnosis to 0.82 (95% CI 0.80, 0.85) (Fig. 2).
There was an inverse relationship between time since last CVD
procedure and resection, with the hazard ratio of resection (CVD
procedure vs. no CVD) close to 1 for patients treated recently,
whilst those who were treated more than 5 years prior to NSCLC
diagnosis were less likely to be resected (Supplementary Fig. 2).
Patients who had received a CABG had a lower rate of resection
than PCI patients (Supplementary Fig. 3). Resection laterality was
not associated with resection rate for patients with CABG
comorbidity (Χ2 p value= 0.118). We did not find a significant
difference between resection rates for NSCLC patients who had
CABG and those who had valve surgery (Χ2 p value= 0.664).
Patients diagnosed with congestive cardiac failure had the lowest
rate of resection compared to other CVD diagnoses
Table 1. Resection rates by cancer stage and CVD comorbidity before NSCLC diagnosis (n= 161,231).
Cancer stage Resection rates, n (%)
CVD procedure CVD diseasea Other CVD codeb No CVD codes
n No. with resection (%) n No. with resection (%) n No. with resection (%) n No. with resection (%)
1 2194 974 (44.4) 12,350 5174 (41.9) 3844 2232 (58.1) 7565 4749 (62.8)
2 967 426 (44.1) 5492 1952 (35.5) 1923 965 (50.2) 4485 2581 (57.5)
3A 1387 197 (14.2) 7650 1068 (14.0) 2656 524 (19.7) 6860 1527 (22.3)
3B 852 11 (1.3) 4996 62 (1.2) 1560 41 (2.6) 4 904 97 (2.0)
4 4725 61 (1.3) 31,894 332 (1.0) 11,377 156 (1.4) 28,558 502 (1.8)
Missing 905 66 (7.3) 7842 326 (4.2) 1841 139 (7.6) 4404 324 (7.4)
Total 11,030 1735 (15.7) 70,224 8914 (12.7) 23,201 4057 (17.5) 56,776 9780 (17.2)
CVD procedures: CABG, PCI or valve surgery.
CVD cardiovascular disease, NSCLC non-small-cell lung cancer, CABG coronary artery bypass graft, PCI percutaneous coronary interventions.
aCVD diagnosis codes excluding CVD procedures and only hypertension.
bPatients with only hypertension, or other CVD procedure (not CABG, PCI or valve replacement).
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Fig. 2 Association between CVD procedure or diagnosis and time from NSCLC diagnosis to resection, compared to no CVD, in
progressively adjusted models (n= 48,950)*. *Excluding patients with cancer stage 3B, 4 or missing and patients with only hypertension or
non-interventional procedure. CVD procedures: CABG, PCI or valve surgery, CVD cardiovascular disease, IMD Index of Multiple Deprivation, CCI
Charlson Comorbidity Index (excluding CVD).
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Fig. 1 Standardised resection ratio for each Clinical Commissioning Group adjusting for variables listed in the title of each graph,
excluding patients with cancer stage 3B, 4 or missing (n= 57,373). CVD cardiovascular disease comorbidity before cancer diagnosis, IMD
Index of Multiple Deprivation, CCI Charlson Comorbidity Index (excluding CVD). Red points indicate geographical regions (i.e. clinical
commissioning groups) with greater than three standard deviations from target standardised resection ratio of 1. Points with the same
number indicate the same region in each funnel plot.
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(Supplementary Fig. 4). Patients with only hypertension recorded
had a slightly higher rate of resection compared to patients with
no CVD (Supplementary Fig. 4).
Risk of mortality
The mortality rate was higher in patients with CVD procedures or
diagnoses compared to patients with no CVD, both prior to or
without resection (Supplementary Fig. 5) and following resection
(Fig. 3). The 30-day post-resection mortality rate increased from
1.5% in patients with no CVD to 2.5% in patients with CVD
diagnoses (odds ratio 1.69; 95% CI 1.34−2.14), after adjusting for
case-mix (Supplementary Table 6).
Increasing propensity for resection
For the CVD comorbid population, mean resection rates in regions
in the lowest fifth and highest fifth were 24% and 47%,
respectively, amongst patients with stages 1, 2 or 3A NSCLC, with
30-day post-operative mortality rates of 2.6% and 3.1%, respec-
tively. Increasing the propensity for resection in patients in regions
in the lowest fifth to the level of the highest fifth would,
conditional on patient mix, increase estimated resection rates
from 24 to 44% (an increase of 20 percentage points) (Fig. 4) and
30-day post-operative mortality to 3.2% (an increase of 0.5%).
Differences in mortality are not evident until after the first year
despite the majority of resections occurring early after diagnosis.
These additional resections would be predicted to increase overall
1-year survival from 61 to 63% and 5-year survival from 21 to 23%
(Fig. 4, red vs. blue lines). The 5-year restricted mean survival
would increase by 0.14 years (95% CI 0.05−0.21) from 2.16 to 2.30
years. The overall effect on 1-year outcomes of increasing
resection rates in this group of patients is highlighted in Fig. 5.
For every 100 patients with diagnosed NSCLC in regions in the
lowest fifth of resection rates, approximately 39 will die within 1
year (3 following resection) and 21 will have been resected and
survived. Increasing resection rates in this population is predicted
to reduce overall 1-year deaths to 37 (7 following resection) with
37 having been resected and survived.
Patients resident in regions with the highest resection rates
have slightly better survival (65% at 1 year and 32% at 5 years),
due to a more favourable case-mix, with a mean restricted survival
(at 5 years) of 2.65 years (Fig. 4, green line). Similar results were
observed when we repeated the analysis using the whole NSCLC
population, shown in Supplementary Fig. 6.
Sensitivity analysis
The hazard ratios and confidence intervals from fitting the Cox
proportional hazard models, investigating the association
between CVD comorbidity and time from NSCLC diagnosis to
resection, were similar when we included (Fig. 2) or excluded
(Supplementary Fig. 7) NSCLC patients with cancer stage 3A.
DISCUSSION
Understanding to what extent CVD comorbidities affect referral for
and outcomes from NSCLC resection is a vital element in trying to
address apparent variations in clinical practice. In this paper we
use linked NCRAS and HES data to demonstrate: firstly, that CVD
comorbidities (whether in the form of previous procedures/
surgery or clinical diagnosis codes) increase early diagnosis of
NSCLC; secondly, that CVD comorbidities reduce the likelihood of
lung cancer resection; thirdly, CVD comorbidities worsen survival
prognosis in both resected and non-resected populations and
finally that increasing resection rates in patients with CVD
comorbidities may offer small but potentially important
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Fig. 3 Association between CVD procedure or diagnosis and time from resection to mortality, compared to no CVD codes, in
progressively adjusted models (n= 18,648)*. *Excluding patients with cancer stage 3B, 4 or missing and patients with only hypertension or
non-interventional procedure. CVD procedures: CABG, PCI or valve surgery, CVD cardiovascular disease, IMD Index of Multiple Deprivation, CCI
Charlson Comorbidity Index (excluding CVD).
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improvements in overall survival with a sizeable increase in
patients treated with surgery with curative intent. In absolute
terms, for CVD comorbid patients with NSCLC, for every ten
additional resections, one death could be avoided by 5 years.
Variation in other aspects of the treatment of lung cancer
patients has been well documented.6,18 Studies of NSCLC in
England report variable lung cancer surgical resection rates by
primary care trust (PCT)7 and treating surgical unit.6 Our study
confirmed wide variation by area of residence. Whilst previous
work showed that this variation is not fully explained by overall
rates of comorbidity (usually described by a derived Charlson
Index), this study extends these findings to investigate the specific
impact of rates of CVD comorbidity. We have demonstrated that
CVD comorbidity explains 1.9% of the overall variation in resection
rate and geographical variation is not well explained by variation
in incidence of CVD comorbidities. We observed that age was the
biggest contributor to geographical variation in resection rates.
Age is a non-modifiable risk factor, but we know that high volume
thoracic surgical centres treat more older patients than the low
volume ones,7 so the clinical management of older patients is
certainly modifiable.
We found resection rate of 39% in England for patients with
stages 1, 2 or 3A NSCLC from 2012 to 2016, which is an increase in
resection rates compared to studies using earlier data, but still low
compared to some other European studies. For stages 1 and 2
NSCLC, resection rates were 27% in Sweden,19 60% in the
Netherlands20 and 67% in Italy.10 These studies suggest possible
reasons for lower resection rates in the UK may be due to fewer
multidisciplinary teams, less frequent imaging and lower diagnosis
volume. These suggestions agree with recommendations from a
report to improve care for lung cancer patients in the UK.21
However, even though the study from the Netherlands found
higher resection rates for hospitals with a teaching status for
thoracic surgeons and high diagnostic volume, hospital teaching
status and volume did not explain variation in resection rates
between hospitals.20
We observed an inverse association between CVD comorbidity
and cancer stage. Patients with CVD comorbidity were more likely
to have a lower cancer stage compared to patients with no CVD
comorbidity. Diagnosis earlier in the natural history of the cancer
is likely to be a result of more intensive hospital investigations
relating to the CVD comorbidity, resulting in earlier, incidental
detection of the tumour, which may increase survival.10
Patients who had received a CABG had a lower rate of resection
compared to PCI patients, possibly because CABG patients
generally have more advanced/complex coronary artery disease
than PCI patients. Another concern might be the technical
challenges of lung resection post CABG (e.g., due to pleural
adhesions or the risk of injury to patent mammary grafts during
upper lobe resections).
A recent study investigated the association between age,
deprivation and CVD comorbid conditions and NSCLC resection in
England and found strong evidence that comorbidities reduced
the receipt of surgery in early-stage patients,22 which agrees with
our study. However, using the multi-state framework to model the
patient care pathway allowed us not only to report survival for
resected and non-resected patients, but also investigate how
increasing resection rates affects survival. A strength of this study
is we were able to analyse large-scale national linked cancer and
hospital episode data within a multi-state modelling framework to
estimate outcomes in the presence of competing risks. Marginal
effects associated with increasing resection rates in different
populations were estimated by “moving” patients from one
regional fifth to another and using standardisation to control for
other modelled patient factors. An assumption of this approach is
that effects are exchangeable when moving patients from one
regional fifth to another, conditional on their covariate pattern.
There are some limitations of this study. First, we were unable to
include WHO performance status classification due to high
proportion of patients with missing values, which has been
shown to be associated with resection rates.22 Second, smoking
status is unavailable, which is likely to be associated with CVD
comorbidity (particularly COPD) and resection rate, but IMD may
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be a suitable proxy for some health and lifestyle choices. Third, we
could only identify CVD comorbidity for NSCLC patients with a
previous hospital admission because we used the in-patient HES
dataset, extracted directly from individual hospital patient
administration systems, and missed patients who never had a
hospital admission over the time period of our study. The results
from previous work, validating the use of HES to identify patients
with myocardial infarction,23 suggest we potentially missed some
CVD events. The only other potential source to identify these
missing patients would be the out-patient HES dataset, which we
Key
Diagnosed not resected
Resected and alive
Resected and dead
Not resected and dead
Fig. 5 Predicted outcomes for NSCLC patients one year after cancer diagnosis. The 100 faces represent the percentage of patients with
outcomes as identified in the key. Top panel: patients in the regional fifth with the lowest resection rate. Bottom panel: patients in the regional
fifth with the lowest resection rate if they had the same resection rate as the regional fifty with the highest resection rate.
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did not use because it is known to have limited diagnoses data.
However, we did use all the in-patient HES records available to us
to maximise the chance of capturing every CVD event. We
excluded CVD events at the time of cancer diagnosis to ensure
CVD was before cancer diagnosis and not a CVD event caused by
cancer treatment (this approach was used by other studies18,22).
Another limitation of using HES to identify CVD comorbidity is we
were not able to obtain details of severity. Fourth, we were not
able to consider other potentially curative treatments (such as
radical radiotherapy or chemotherapy), which may be more
suitable for patients with early-stage NSCLC than resection.
However, a recent study24 examined variation in resection rates
and radical radiotherapy rates for English NSCLC patients using
NCRAS did not find an association between resection rates and
radical radiotherapy rates, suggesting areas with low resection
rates do not necessarily have high radical radiotherapy rates.
Finally, NSCLC patients with cancer stage 3A may be a
heterogeneous group because the standard of care is not
consistent in England, but repeating the analysis excluding
patients with cancer stage 3A did not alter the interpretation of
the results.
In conclusion, this study found CVD comorbidity did not
substantially explain resection rate variation and a small but
significant increase in survival was predicted when we modelled
an increased propensity for resection in CVD comorbid patients in
regions with lowest resection rates. Our findings suggest that
decision-making about resection in CVD comorbid patients is
overly conservative and that increasing resection rates in CVD
comorbid patients, at least to the level currently seen in those
regions in the top fifth for resections in this population, will
improve population-level survival. Further work is required to
understand the reasons for variation in cancer treatment and how
best to ensure that all patients have access to optimal care, which
may be treatments other than resection.
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